Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis.
• Current immunotherapies like PD-1/PD-L1 inhibitors show modest response rates in TNBC.
• Novel therapeutic strategies are urgently needed to improve outcomes for TNBC patients.

Purpose of the Study:

• To investigate the efficacy of a novel nanovaccine strategy for treating triple-negative breast cancer.
• To evaluate the synergistic effects of combining nanoparticle-based vaccines with immune checkpoint agonists.

Main Methods:

• Development of polymeric nanoparticles (NPs) co-entrapping tumor antigens, Toll-like receptor ligands, and siRNA targeting TGF-β1.
• Treatment of TNBC models with the engineered nanovaccines and an OX40 agonist.
• Assessment of anti-tumor immune responses, tumor growth inhibition, and overall survival.

Main Results:

• Nanovaccine-mediated TGF-β1 silencing in dendritic cells sensitized TNBC to OX40 agonist therapy.
• Combination therapy significantly inhibited tumor growth and increased overall survival in preclinical models.
• Similar anti-tumor effects were observed in a luminal mammary cancer model.

Conclusions:

• Synergistic anti-cancer effects were achieved through combined nanovaccine-induced adaptive immunity and OX40 immune checkpoint activation.
• This novel combination regimen holds potential for improving treatment response rates in aggressive breast cancers.
• Further development of nanovaccine-based combination therapies could offer new hope for TNBC patients.